肿瘤抑制通路塑造了表皮生长因子受体（EGFR）驱动的肺癌进展及对治疗的反应。
Tumor suppressor pathways shape EGFR-driven lung tumor progression and response to treatment.
作者信息
Foggetti Giorgia, Li Chuan, Cai Hongchen, Petrov Dmitri A, Winslow Monte M, Politi Katerina
机构信息
Department of Internal Medicine (Medical Oncology), Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA.
Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
出版信息
Mol Cell Oncol. 2022 Jan 14;9(1):1994328. doi: 10.1080/23723556.2021.1994328. eCollection 2022.
modeling combined with CRISPR/Cas9-mediated somatic genome editing has contributed to elucidating the functional importance of specific genetic alterations in human tumors. Our recent work uncovered tumor suppressor pathways that affect EGFR-driven lung tumor growth and sensitivity to tyrosine kinase inhibitors and reflect the mutational landscape and treatment outcomes in the human disease.
结合CRISPR/Cas9介导的体细胞基因组编辑的建模有助于阐明特定基因改变在人类肿瘤中的功能重要性。我们最近的工作发现了影响表皮生长因子受体（EGFR）驱动的肺癌生长以及对酪氨酸激酶抑制剂敏感性的肿瘤抑制途径，并且反映了人类疾病中的突变格局和治疗结果。
Zotero 插件